Clinical-Stage Messenger Ribonucleic Acid (mRNA) Therapeutic Platform Market Global Report 2026

The clinical-stage messenger ribonucleic acid (mRNA) therapeutic platform market size has grown rapidly in recent years. It will grow from $22.09 billion in 2025 to $25.75 billion in 2026 at a compound annual growth rate (CAGR) of 16.5%. The growth during the historic period was driven by increasing investments in biotechnology research, rising adoption of mRNA vaccine technologies, growing demand for advanced therapeutic solutions, expansion of clinical research activities, and increasing focus on targeted disease treatment approaches.

The clinical-stage messenger ribonucleic acid (mRNA) therapeutic platform market size is expected to see rapid growth in the next few years. It will grow to $46.79 billion in 2030 at a compound annual growth rate (CAGR) of 16.1%. The growth during the forecast period can be attributed to growing development of mRNA therapies for complex diseases, increasing investments in novel delivery platforms, rising adoption of personalized medicine solutions, expanding clinical pipelines for rare and chronic diseases, and increasing commercialization of mRNA-based therapeutics. Major trends during the forecast period include increasing development of next-generation mRNA therapeutic platforms, growing adoption of advanced mRNA delivery technologies, rising expansion of clinical trials for mRNA-based therapies, increasing focus on personalized mRNA medicine approaches, and growing innovation in stable and efficient mRNA formulations.

The increasing demand for personalized medicine is expected to drive the growth of the clinical-stage messenger ribonucleic acid (mRNA) therapeutic platform market in the coming years. Personalized medicine refers to a healthcare approach that customizes disease prevention, diagnosis, and treatment strategies based on an individual’s genetic makeup, lifestyle, and environmental influences to achieve improved clinical outcomes. The demand for personalized medicine is rising due to the increasing incidence of chronic and complex diseases that require targeted treatment solutions and accurate diagnostic methods. Clinical-stage messenger ribonucleic acid (mRNA) therapeutic platforms support personalized medicine by enabling the rapid development and production of patient-specific or disease-specific therapies tailored to an individual’s genetic profile, immune response, and disease characteristics. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 new personalized therapies for rare disease patients in 2023, representing a significant increase compared to the six approvals in 2022. Therefore, the increasing demand for personalized medicine is driving the growth of the clinical-stage messenger ribonucleic acid (mRNA) therapeutic platform market.

Major companies operating in the clinical-stage messenger ribonucleic acid (mRNA) therapeutic platform market are concentrating on the development of advanced platforms, including AI-powered mRNA platforms, to accelerate drug discovery, enhance therapeutic accuracy, and improve treatment outcomes for oncology and autoimmune disease applications. AI-powered mRNA platforms integrate artificial intelligence, mRNA engineering, and targeted delivery technologies to facilitate the rapid development of personalized vaccines and next-generation cellular therapies. For instance, in July 2025, Everest Medicines Limited, a China-based biopharmaceutical company, presented advancements in its proprietary AI+mRNA platform during its 2025 research and development day in Shanghai. The company highlighted progress in personalized cancer vaccine EVM16, tumor-associated antigen vaccine EVM14, and its in vivo CAR-T therapy platform. The platform combines the EVER-NEO-1 AI neoantigen prediction algorithm, third-generation mRNA sequence optimization technology, and targeted lipid nanoparticle delivery systems to enhance immunogenicity, tissue-specific delivery, and therapeutic performance. The technology is designed to support diverse oncology and autoimmune disease applications by enabling stronger immune responses, improved CAR expression efficiency, and faster development of precision therapeutics.

In June 2025, BioNTech SE, a Germany-based biotechnology company, acquired CureVac for an undisclosed amount. Through this acquisition, BioNTech aims to strengthen its messenger ribonucleic acid-based oncology and cancer immunotherapy capabilities by integrating CureVac’s messenger ribonucleic acid research, development, and manufacturing technologies while expanding its clinical-stage therapeutic pipeline. CureVac N.V. is a Germany-based biotechnology company specializing in a comprehensive proprietary messenger RNA (mRNA) therapeutic and vaccine platform.

Major companies operating in the clinical-stage messenger ribonucleic acid (mrna) therapeutic platform market are Arcturus Therapeutics, BioNTech SE, Ethris GmbH, HDT Bio Corp., Kernal Biologics Inc., Moderna Inc., Pfizer Inc., Providence Therapeutics Inc., Replicate Bioscience Inc., Strand Therapeutics Inc., Walvax Biotechnology Co Ltd.

North America was the dominating region in the clinical-stage messenger ribonucleic acid (mRNA) therapeutic platform market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the clinical-stage messenger ribonucleic acid (mRNA) therapeutic platform market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the clinical-stage messenger ribonucleic acid (mRNA) therapeutic platform market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The clinical-stage messenger ribonucleic acid (mRNA) therapeutic platform market includes revenues earned by entities by providing services such as messenger ribonucleic acid therapeutic development services, clinical research services, delivery platform services, contract development and manufacturing services, regulatory support services, and personalized therapeutic solution services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

This product will be delivered within 3-5 business days.